| NCT ID | NCT07024927 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Beijing Anzhen Hospital |
| Condition | Atrial Fibrillation (AF) |
| Study Type | OBSERVATIONAL |
| Enrollment | 4,000 participants |
| Start Date | 2025-10-21 |
| Primary Completion | 2032-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 4,000 participants in total. It began in 2025-10-21 with a primary completion date of 2032-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a prospective, non-randomized, multicenter observational registry study designed to systematically evaluate the long-term efficacy and safety of catheter ablation for treating atrial fibrillation (AF) and ventricular tachycardia (VT) in Chinese patients.
Eligibility Criteria
1. Atrial Fibrillation (AF) Cohort: * Inclusion Criteria (Patients must meet ALL of the following criteria): 1. Age ≥ 18 years. 2. Diagnosed with atrial fibrillation (AF), including paroxysmal AF (PAF) and persistent AF (PsAF). 3. Scheduled to undergo first-time catheter ablation for AF. 4. Procedure to be performed using a 3D mapping system. 5. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments. * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded): 1. Severe congenital heart disease (e.g., Tetralogy of Fallot, corrected transposition of the great arteries). 2. AF secondary to a clearly reversible cause (e.g., hyperthyroidism, post-operative state, acute alcohol intoxication). 3. Unstable angina pectoris or acute myocardial infarction (MI) within 30 days prior to enrollment/procedure. 4. Severe active infection (e.g., septic shock, sepsis). 5. Contraindications to anticoagulation therapy. 6. Current participation in another interventional clinical trial that may confound the results of this study. 7. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study. 2. Ventricular Tachycardia (VT) Cohort * Inclusion Criteria (Patients must meet ALL of the following criteria): 1. Age ≥ 18 years. 2. Diagnosed with ventricular tachycardia (VT) associated with underlying structural heart disease, including: 3. Ischemic heart disease (e.g., prior MI, coronary artery disease). 4. Non-ischemic cardiomyopathy (e.g., dilated cardiomyopathy (DCM), arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM)). 5. Scheduled to undergo first-time catheter ablation for VT. 6. Procedure to be performed using a 3D mapping system. 7. Provision of signed written informed consent for study participation and willingness and ability to comply with all protocol-required follow-up assessments. * Exclusion Criteria (Patients meeting ANY of the following criteria will be excluded): 1. VT due to a transient or reversible cause (e.g., acute myocardial ischemia, severe electrolyte imbalance). 2. Idiopathic ventricular tachycardia (VT occurring in the absence of structural heart disease). 3. Cardiac surgery within 60 days prior to the planned ablation procedure. 4. Severe coagulopathy (e.g., platelet count \< 50 x 10⁹/L, disseminated intravascular coagulation (DIC)). 5. Severe heart failure with left ventricular ejection fraction (LVEF) \< 20%. 6. Severe active infection (e.g., septic shock, sepsis). 7. Current participation in another interventional clinical trial that may confound the results of this study. 8. Any other condition where, in the investigator's judgment, the patient is unsuitable for participation in this study.
Contact & Investigator
Deyong Long
PRINCIPAL INVESTIGATOR
Beijing Anzhen Hospital
Frequently Asked Questions
Who can join the NCT07024927 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Atrial Fibrillation (AF). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07024927 currently recruiting?
Yes, NCT07024927 is actively recruiting participants. Contact the research team at dragon2008@vip.sina.com for enrollment information.
Where is the NCT07024927 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China.
Who is sponsoring the NCT07024927 clinical trial?
NCT07024927 is sponsored by Beijing Anzhen Hospital. The principal investigator is Deyong Long at Beijing Anzhen Hospital. The trial plans to enroll 4,000 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.